5 results match your criteria: "The Fifth Affiliated Hospital of Zhongshan University[Affiliation]"
Increased serum concentrations of Mesencephalic astrocyte-derived neurotrophic factor in patients and rats with ischemic stroke.
J Stroke Cerebrovasc Dis
November 2022
Department of Neurology, The First Affiliated Hospital of Harbin Medical University, 150001, Harbin, Heilongjiang, China. Electronic address:
Objectives: Although Mesencephalic astrocyte-derived neurotrophic factor (MANF) shows protection in multiple cells, the role of circulating MANF in patients with acute ischemic stroke (AIS) and transient ischemic attack (TIA) remains unclear. Here, we aimed to explore the value of circulating MANF levels in cerebral ischemic events.
Materials And Methods: Using a rat cerebral ischemic model, MANF expression in ischemic brains and serum was detected.
[Effect of Shuxuetong injection on neuron-specific enolase of serum and recovery of function in patients with acute cerebral infarction].
Zhongguo Zhong Yao Za Zhi
September 2011
The Fifth Affiliated Hospital of Zhongshan University, Zhuhai 519000, China.
Objective: To observe the clinical effect and the influences of Shuxuetong injection on serum neuron-specific enolase (NSE) level, the neurological deficit and activities of daily living in patients with acute cerebral infarction.
Method: The 80 patients with acute cerebral infarction were randomly divided into Shuxuetong treatment group (40 cases) and routine control group (40 cases), both received routine treatment, while Shuxuetong injection was given additionally to treatment group. The serum NSE level, the National Insitute of Health Stroke Scale (NIHSS) scores and the clinical effect were observed pre-and post-treatment.
Renal hemodynamic changes with aging: a preliminary study using CT perfusion in the healthy elderly.
Clin Imaging
November 2010
Department of Radiology, The Fifth Affiliated Hospital of Zhongshan University, Zhuhai 519000, PR China.
Objective: To investigate renal blood flow perfusion parameter changes associated with aging using multislice spiral computed tomography (CT).
Methods: This prospective study was approved by the institute's ethics committee for clinical study and written informed consent was obtained from all subjects. Forty-two consecutive patients who underwent abdominal CT without obvious renal abnormality at plain scanning were enrolled in this study.
[A pilot study of using pure albumin as a dialysate in the treatment of liver failure].
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
October 2005
The Center of Blood Purification, The Fifth Affiliated Hospital of Zhongshan University, Zhuhai 519000, Guangdong, China.
Article Synopsis
- The study aims to assess the effects of single albumin dialysis (SAD) compared to the molecular absorbent recycling system (MARS) in treating liver failure patients.
- Eighteen patients were treated with either SAD or MARS for 6 hours, monitoring various liver and kidney functions, as well as other critical health markers throughout the sessions.
- Results indicated that SAD significantly improved clinical symptoms and liver function with fewer complications and at a lower cost than MARS, suggesting it is a viable option for treating liver failure and warrants further research.
[Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication].
Zhonghua Gan Zang Bing Za Zhi
October 2004
The Fifth Affiliated Hospital of Zhongshan University, Zhuhai 519000, China.
Objective: To explore a new strategy for effective and economical anti-virus therapy for HBV infection, we conducted a sequence administration of lamivudine and interferon alpha 1b to evaluate its effects on HBV replication and rebound as well as YMDD mutation induced by lamivudine.
Methods: 150 HBV patients having at least 6 months history of infection were assigned randomly into 5 groups. Each group of these patients was either treated with lamivudine, interferon alpha 1b, lamivudine combined with interferon, sequence administration of lamivudine and interferon (sequence group) or no anti-virus therapy (control group) for 12 months.